Ind-Swift has launched generic formulation of the world’s best selling drug -- Atorvastation -- in UK in collaboration with Wockhardt UK on the first day of its patent expiry. Atorvastation is the world’s best selling drug with the world market size of $16 billion.
The drug went off patent in Europe on May 6, 2012 and taking this opportunity Ind Swift and its EU marketing partner Wockhardt UK launched the generic vwersion of the molecule in UK on the day after its patent expiry.
The product was launched in all its strengths i.e. 10mg, 40mg and 80mg.
Ind-Swift is a fully integrated pharma group. The API required for the product was supplied from the USFDA and MHRA approved plant of Ind-Swif Laboratories and the formulations was manufactured and supplied from the 100% export facility of Ind-Swift located near Derabassi Punjab.
